RESEARCH TRIANGLE PARK – Gene editing startup Locus Biosciences is another step closer to actualizing its biotherapeutics against bacterial diseases after landing $35 million in additional capital.
When something goes wrong, it’s natural to cast blame on the perceived cause of the misfortune. Where an individual casts that blame can be related, in many cases, to a psychological construct known ...
Locus Pharmaceuticals Completes $30.2 Million Financing Round Locus Pharmaceuticals, Inc., a computationally based drug design and development company, announced today that it has closed on a $30.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback